Isaksen
TL3 Regular · Nice, FR
Pharmacist. Answers stability and compatibility questions and declines to answer clinical ones.
Joined 26 September 2024 · last posted 4h · groups: pharmacists
126Posts here
3Topics
2Solutions
5.3kLikes received
4.5kLikes given
27Badges
436Days visited
12kPosts read
Stated areas
Recent activity
Full stream-
Mobile reading experience on long topics Replied, post #3 · Meta › Site feedback · 28 Jul 2026 · 5 likes I had read the opposite somewhere and cannot now find where, which tells me something.
-
Solubility limits and what a cloudy solution is telling you Replied, post #16 · Pharmacology › Formulation chemistry · 27 Jul 2026 · 3 likes Overfill in a vial is deliberate and accounts for the volume unrecoverable at the end. It is not generosity and it is not a bonus dose.
-
Subgroup analyses: pre-specified versus discovered Replied, post #3 · Evidence › Trials · 27 Jul 2026 · 10 likes The opening post put the caveat in the right place and I want to underline it. Subgroup analyses are hypothesis-generating unless pre-specified and adequately powered,…
-
Coming back to: Where the four-week escalation interval comes from, and what it is not Replied, post #43 · Practice › Dosing & titration · 23 Jul 2026 · 18 likes The four-week step is a trial convention, not a pharmacological constant. It is roughly four half-lives for a week-long half-life, which is the interval at which you…
-
Revisiting: Liver enzymes drifting down and what that usually means Replied, post #60 · Clinical › Bloodwork · 23 Jul 2026 · 18 likes Confirming post #59 from a second method, which matters more than confirming it from a second person. Reference intervals: constructed to contain the central 95% of a…
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #51 · Access › Insurance & coverage · 21 Jul 2026 · 12 likes Tier placement and step therapy: some formularies place a medication on a higher tier or require you to fail cheaper alternatives before approving the one you want.…
-
Insurance and replacement policies, compared Replied, post #97 · Sourcing › Logistics · 18 Jul 2026 · 32 likes Worth separating two things that post #96 runs together. Insurance and replacement policies was covered in the wiki last year and the page has a review date on it,…
-
Journal club: orforglipron phase 2 and the non-peptide question Replied, post #123 · Evidence › Journal club · 17 Jul 2026 · 0 likes Post #122 answers the question as asked. The question underneath it is different. Critical appraisal template: (1) What did the trial set out to estimate? (2) Could the…
-
Primary endpoint hierarchies and why order matters — one year on Replied, post #48 · Evidence › Trials · 16 Jul 2026 · 0 likes Post #45 put the caveat in the right place and I want to underline it. Genuine question rather than a rhetorical one: has anyone here actually observed Primary endpoint…
-
Common supplements people ask about, assessed one at a time Replied, post #42 · Practice › Interactions · 13 Jul 2026 · 3 likes Taking post #41 at face value and following it one step further. A pharmacist can answer most questions in this subcategory in a few minutes with access to a proper…
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #73 · Analytics › Impurities & related substances · 13 Jul 2026 · 18 likes That is a fair summary of where the discussion has got to.
-
Follow-up: How compounding permissions changed when supply normalised Replied, post #14 · Sourcing › Regulatory · 12 Jul 2026 · 2 likes Nothing in this subcategory is legal advice, and the members who work in regulated environments are the most careful to say so.